Kornimate/medical-research-clean huggingface dataset:
immunotherapy using pluripotent killer-programmed cell death 1 (pik-pd-1) cells for the treatment of advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: objectives: the purpose of this study is to evaluate the safety and efficacy of pik-pd-1 cells in the treatment of advanced hepatocellular carcinoma. methods: this study designs a novel therapy using pik-pd-1 cells. 40 patients with advanced hepatocellular carcinoma will be enrolled. they are randomly divided into dendritic cell-precision multiple antigen t cells (dc-pmat) group and pik-pd-1 cells group. both dc-pmat treatment and pik-pd-1 cells treatment will be performed every 3 weeks with a total of three periods. the mail clinical indicators are progression-free-survival and overall survival.

a total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility criteria:
inclusion criteria: * 1. age 20\~70 years old, male or female; 2. barcelona clinic liver cancer(bclc) c stage; no indication for operation, local treatment (transcatheter arterial chemoembolization (tace), percutaneous icro wave coagulation therapy (pmct), percutaneous ethanol injection therapy (peit)) and radiation therapy; unable or unwilling to receive sorafenib therapy; 3.child-pugh score ≤ 9; 4.eastern cooperative oncology group (ecog) score ≤ 2; 5.life expectancy\>3 months; 6. white blood cell (wbc) \> 3 x 10\*9/l, neutrophils \> 1 x 10\*9/l, lymphocyte \> 1 x 10\*9/l, hemoglobin ≥8.5g/dl, platelet ≥50×109/l, prothrombin time (pt) no more than 3 seconds, cr and blood urea nitrogen (bun) less than 3 times of the normal level; 7. adequate venous access, blood cell production without other taboos; 8. signed informed consent. exclusion criteria: * 1. immunosuppressive therapy needed with autoimmune disease or organ transplantation history； 2. hiv/syphilis infection; 3. positive blood culture or imaging evidence infection; 4. other drugs, gene therapy, biological, chemotherapy or radiation therapy were used within 1 months. 5. the history of allergic reactions in cell therapy or cytokine. 6. pd-1 antibodies have been used before, or allergies due to pd-1 antibody drugs. 7. history of interstitial lung disease. 8. history of esophagus varicosis rupture haemorrhage. 9. other serious diseases:the heart,lung, kidney, digestive, nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc. 10. pregnant, lactating women, or pregnancy planned at the following 2 years. 11. without signed informed consent. 12. other researchers considered ones unsuitable for inclusion.

Keywords: pik-pd-1 cells dendritic cell-precision multiple antigen t cells advanced hepatocellular carcinoma
hyaluronic acid injection in the glans penis versus selective serotonin reuptake inhibitors for lifelong premature

Conditions: Selective Serotonin Reuptake Inhibitor; Hyaluronic Acid; Glans Penis; Lifelong Premature

Summary: the aim of this study was to compare the effectiveness and safety of selective serotonin reuptake inhibitors (dapoxetine) and hyaluronic acid gel injection in the glans penis for lifelong premature.

over the past 30 years, the common knowledge of premature ejaculation (pe) has advanced strikingly. pe is a very common and upsetting sexual male dysfunction. it is disturbing for both partners affecting their sexual experience, reducing their quality of life up to sexual abstinence, causing lack of self-confidence and even depression. it has a prevalence of a variable range, yet it is thought that one third of all males might complain of pe at a certain point throughout their lives and the incidence is rising. many treatment modalities have been currently used for pe varying from behavioral therapy to medical treatment and finally surgical therapy. methods of behavioral therapy are: squeeze technique and start/stop technique. pharmacological therapies include: nonselective and selective ssris, topical therapy with anesthetics, pde5 inhibitors, opioid agonists and others. as for surgical modalities for pe there are several techniques including: glans augmentation, frenectomy, dorsal selective neurectomy, pulsed radiofrequency neuromodulation, removal of foreskin remnants and varicocelectomy.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * males. * suffering from lifelong premature ejaculation not responding to the behavioral therapy. exclusion criteria: * erectile dysfunction. * prostatitis. * acquired premature ejaculation. * addiction. * psychiatric disorders (e.g., schizophrenia, bipolar disorder, and other psychoses). * historical use of ejaculatory medication within the previous three months.
elaboration of a pre-surgery mapping protocol of primary motor cortex, prior to an implementation of a stimulation of primary motor cortex for patients with deafferentiation of brachial plexus pain

Conditions: Painful Avulsion of Brachial Plexus

Summary: in the context of an insufficiency of clinical results for cortical stimulation in treatment of brachial plexus post-avulsion pains, one of the possibility for failure is the bad pre-surgery mapping of the area to stimulated bu the usual methods (pem et fmri). this purpose of this study is to realise a precise mapping of the primary motor cortex post brachial plexus avulsion. the principal endpoints is to identify and test the reliability of a muscular marker for which the cortical representation is localized immediately next to the superior member area. several muscles of cephalic, cervical and chest area will be investigate. the methods used will be mono-shock transcranial magnetic stimulation (mtms) and functional mri. concerning mtms, several methods will be tested: best position on the scalp, realisation of outputs maps with extreme points average method, with mass center method. concerning fmri studies, the above paradigms will be checked: imaginary movements of hand, blow up and down abdomen, eyes winking. statistical tests will confirm the best muscle candidate and will permit to evaluate the reliability of the method.


Eligibility criteria:
inclusion criteria: * for all groups: informed consent, social insurance * for group 1 "painful bpa": consulting to the nantes'uh for pain of bpa, eva≥4, neurological deficiency partial or total * for group 2 "painless bpa": eva\<4, neurological deficiency partial or total, matching with group 1 on the neurological deficiency * for group 3 "healthy": matching with group 1 on age ±10 years exclusion criteria: * no informed consent * medical history of epilepsy * pregnant women * contra-indication to mri
the effect of 6% hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients medicated with antiplatelet agents prior to off-pump coronary bypass graft surgery

Conditions: Coronary Artery Occlusive Disease

Summary: hes 130/0.4 significantly solution will not affect on coagulation and blood loss in patients medicated with antiplatelet agents prior to off-pump coronary bypass surgery (opcab).


Eligibility criteria:
inclusion criteria: * eighty patients undergoing opcab, who were exposed to anti platelet agents until 5 days prior to surgery were randomly allocated to infuse hes 130/0.4 up to 30 ml/kg and followed crystalloid infusion or infuse crystalloid only during perioperative period, exclusion criteria: patient who has * valvular disease of heart * mi within 3 months,patient under 40% of left ventricle preoperative output * left main artery stenosis * anemia (hemoglobin \ 80sec, serum creatinine \> 1.2 mg/dl, respiratory disease(asthma, copd, pao2 \< 70 mmhg, pulmonary hypertension or pulmonary edema, etc) * not consented to this trial
open-label study to evaluate clearance of superficial basal cell carcinoma after use of imiquimod 5% cream

Conditions: Superficial Basal Cell Carcinoma

Summary: an open-label study to evaluate the safety and the ability of imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.

evaluate the long-term sustained clearance rate, defined as the proportion of those subjects clinically clear of basal cell carcinoma (bcc) at the treated superficial bcc (sbcc) target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period.

Eligibility criteria:
inclusion criteria: * have at least 1 previously untreated superficial basal cell carcinoma tumor * minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm exclusion criteria: * evidence of clinically significant, unstable medical conditions * cannot have recent use of topical steroids or retinoids in the treatment area.

Keywords: superficial basal cell carcinoma aldara
impact of hand osteoarthritis on arterial stiffness

Conditions: Osteoarthritis

Summary: patients affected by osteoarthritis (oa) have an increase overall mortality compared to the general population, mainly due to cardiovascular diseases. oa patients without cardiovascular risk have a 10 years cardiovascular events higher of around 15-30 %. although the molecular mechanisms are still not well known, the structure and function of the vessel wall can be affected by several inflammatory and metabolic parameters during oa.these functional and structural changes of the arterial wall leads to arterial stiffness, measured by the pulse-wave velocity (pwv). pwv is the most widely used technique to assess arterial stiffness and has been shown to have predictive value for morbidity and mortality. in our study, we planned to compare arterial stiffness in oa patients with healthy subjects.


Eligibility criteria:
inclusion criteria: * patients with clinical hand oa defined according to the acr (american college of rheumatology) criteria. * patients with radiographic hand oa defined according to the kellgren * lawrence criteria (≥ 2). * steady dose of statins for at least one month. * subject affiliated to a social security scheme * written informed consent exclusion criteria: * rheumatoid arthritis, psoriatic arthritis or other inflammatory arthritis diseases. * history of arterial hypertension treated and / or uncontrolled (sbp \> 140 mmhg and dbp (diastolic blood pressure) \> 90 mmhg) * diabetes (fasting blood glucose \> 7 mmol/l) * obesity (bmi \> 35 kg/m²) * chronic renal failure defined by a glomerular filtration rate \<60 ml/min/1,73m ². * patient with uncontrolled cardiovascular disease or a personal history of cardiovascular events (myocardial infarction and angina, occlusive arterial disease, stroke) * pregnant or breastfeeding, or premenopausal and not taking an effective contraception
hazardous surgical smoke: risk assessment and evaluation of a new smoke extractor system in the surgical unit

Conditions: Lung Cancer; Lung Injury

Summary: the investigators will define two separate groups of surgical procedures: 1.) an 'open group' in which mainly open anatomic lung resections will be included, and 2.) a 'minimally invasive' group in which mainly thoracoscopic anatomic lung resections will be included. both groups will then be randomized to either the performance of the surgical procedure under 'standard conditions' or to the performance of the procedure with the additional use of a smoke evacuation system. during every procedure the hazardous smoke that is generated by the electrocautery in the surgical field will be collected through a tube at the height of the surgeons face. the smoke is then directly transferred to a mass spectrometer that is situated in the operating room (or) and performs a real-time analysis of the chemical substances in the air. the degree of air pollution will be measured as well as the smoke evacuation systems' ability to reduce these hazardous chemical substances in the air can be evaluated.

smoke samples will be continuously analyzed with a latest generation time of flight mass spectrometer in real time. concerning the smoke evacuation device, the investigators will use the model ies 2 (intelligent evacuation system) from erbe swiss medical for this study. since this is only an observational study in which the investigators are only recording the type of surgery (i.e. open oder minimally invasive) and not recording sensitive patient data, the local ethics committee waived the need for an ethics committee approval of the study. in the end the smoke evacuation system does not have an effect on the patient or the procedure itself, but may rather influence the concentration of hazardous surgical fumes in the operating theatre.

Eligibility criteria:
inclusion criteria: - all surgical procedures with a planned duration of more than 1 hour exclusion criteria: * patients with a contraindication for electrocautery use * patients with pacemaker or implantable cardioverter-defibrillator (icd) * patients with an implanted neurostimulator device

Keywords: smoke plume electrocautery mass spectrometer
safety, toleration and efficacy of single inhaled doses of pf-00610355 in chronic obstructive pulmonary (copd) patients.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study will look at the pharmacokinetics, safety, toleration and efficacy of pf-00610355 in the chronic obstructive pulmonary disease (copd) population. the doses in this study are intended to explore the anticipated clinical dose range.


Eligibility criteria:
inclusion criteria: * post-bronchodilator fev1/ fvc ratio of \<0.7. * post bronchodilator fev1 of 50-80% (inclusive) of predicted. * body mass index (bmi) of less than 35 kg/m2; and a total body weight greater that 40 kg. * current smokers, or ex-smokers who have abstained from smoking for at least 6 months. exclusion criteria: * subjects having more than 2 exacerbations requiring treatment with oral steroids or hospitalization for the treatment of copd in the previous year. * history of lower respiratory tract infection or significant disease instability during the month preceding screening or during the period between screening and randomization.

Keywords: copd
endometrial local injury before first ivf : evaluation of pregnancy rate

Conditions: Sterility, Female

Summary: in spite of all progress realized in the field of assisted reproduction the pregnancy rate by in vitro fertilization (ivf) in france, across indications, is only 23% after ivf cycle. different causes may account for these failures and that, during all stages of pregnancy. recent studies have investigated an essential step in fecundation : uterine receptivity. some teams have shown that a lot of immunological factors would have very significant in this step, by them possible expression in this process. other studies looked at genes modulation, essential to implantation, with endometrium manipulation, simple, such as endometrial biopsy (eb). the last findings published on this subject, but after 2 ivf failures, are most encouraging because the pregnancy rate for these teams after just endometrial local injury (eb after 2 ivf failures) is well above their usual pregnancy rate. some teams have focused on immunoassay of endometrial biopsy, in order to profile uterine receptivity and suggest with results, suitable treatment for each patient (ongoing study). eb is quick, easy, make in a simple consultation and with a low cost, contrary to immunological study, which depend of ultra-specialized laboratories and therefore with an important cost.


Eligibility criteria:
inclusion criteria: * only first ivf * acceptance of protocol by patient after free and complete information and signature of consent. * anti-mullerian hormone (amh ) greater than 1 * member or eligible to social security system * availabilities for a follow up 2 or 12 months. exclusion criteria: * known intolerance of proposed treatment

Keywords: endometrial biopsy previous ovarian hyperstimulation cycle first ivf antagonist protocol clinical pregnancy rate
surgical treatment for degenerative scoliosis

Conditions: Scoliosis; Kyphoscoliosis

Summary: the study aims to analyze the surgical treatment of low back pain due to degenerative kyphoscoliosis, already routinely performed on patients treated in istituto ortopedico rizzoli, in terms of reduction of the pain and functional improvement. the comparison of back pain and functional ability before and after the surgical treatment will be performed by administering to the patients specific questionnaires (visual analog score vas, oswestry disability index odi, quality of life euroqol 5d). questionnaires administration will be matched to a purely objective and radiological assessment according to international guidelines. a psychological analysis will be also performed in order to evaluate co-morbidity from this field, considering that the concept of "shared decision-making" for the therapeutic approach to low back pain requires the evaluation of all these parameters.


Eligibility criteria:
inclusion criteria: * female or male * age 40-75 years * patients capable of understanding and willing * lumbar or thoraco-lumbar degenerative kyphoscoliosis * chronic low back pain from more than 6 months and/or presence of neurological deficits at lower limbs * failure to respond to conservative therapy exclusion criteria: * infections in place * coagulation deficits * serious psychological comorbidity

Keywords: degenerative scoliosis pain deformity correction instrumented arthrodesis
infantile no replenishment as a new therapeutic possibility

Conditions: Prematurity; Respiratory Distress Syndrome, Newborn

Summary: case-control study of inhaled nitric oxide (ino) treatment of full-term and preterm infants. the main objective of this study is to investigate the association between premature birth and its later comorbidities (neuroendocrine, metabolic, cognitive, etc) with ino treatment and the maturation of the hpg axis during minipuberty.

in preterm infants, inhaled no (ino) is routinely used to treat respiratory failure and pulmonary hypertension, while preclinical studies have shown that it markedly increases no concentrations in the brain. animal and human studies have shown that no deficiency may jeopardize the establishment of a mature and functional hpg axis whereas it is also associated with a series of comorbidities affecting the overall brain development (e.g. sensory, fertility and cognitive functions). prematurity has been associated with a series of non-communicable diseases of major importance in public health, including neurodevelopmental impairments, metabolic abnormalities (e.g. obesity, type 2 diabetes mellitus, impaired glucose tolerance) and cardiovascular disease. this study aims to evaluate the associations between altered minipuberty in preterm infants and the later development of multi-comorbidities (mental and non-mental disorders), and identify the possible implication of the no pathway as a causative mechanism. specific objectives : 1. assess the efficiency of no replenishment therapy (i.e. role of no pathway) as a therapeutic against alterations of minipuberty resulting from preterm birth. 2. assess the efficiency of no replenishment therapy (i.e. role of no pathway) as a therapeutic against the multi-comorbidities (mental and non-mental disorders) related to altered minipuberty as a result of preterm birth.

Eligibility criteria:
inclusion criteria: * preterm (ga\<37 weeks) or full-term (≥37 weeks of gestation) infants * requiring respiratory support * admitted to neonatal care unit exclusion criteria: * severe congenital anomalies * suspected major chromosomal anomalies * infants judged by the physician as nonviable

Keywords: preterm birth neurodevelopment cardiometabolic minipuberty
pharmacokinetics of intranasal ketorolac in children

Conditions: Evaluating Pharmacokinetics of Intranasal Ketorolac; Pain

Summary: ketorolac is a non-steroidal anti-inflammatory drug (nsaid) that is typically given to both adults and children by the intravenous (iv) or intramuscular (im) route for analgesic purposes. ketorolac can also be given by the intranasal (in) route using a mucosal atomization device (mad). we aim to study the pharmacokinetics of ketorolac when administered by the in route using the mad.

the intranasal (in) route of administering medications is an effective means of delivering analgesics to children in a painless and minimally distressing manner, especially in comparison to traditional means of intravenous (iv) or intramuscular (im) administration, which require a painful and distressing needle stick. ketorolac is an analgesic that is commonly administered to children, and can be given by the in route, in addition to the iv and im routes. however, the pharmacokinetics of intranasal ketorolac when administered in children has only been described in a limited fashion. the administration of in ketorolac in children, using the proprietary sprix device, which atomizes a fixed amount of ketorolac, produces serum concentrations of ketorolac that are associated with analgesia. however, the concentrations of ketorolac achieved using a mucosal atomization device (mad) has not yet been evaluated in children presenting to the emergency department. the mad is a plastic device that attaches to the top of a syringe (see figure). the mad is much more commonly used for atomizing medications; allows a variable dosage to be administered; and has been shown to be a means of effectively delivering other analgesics and sedatives intranasally. the purpose of this study is to assess the pharmacokinetics of in ketorolac when using a mad to deliver the medication in children presenting to the emergency department. we will determine the maximum serum concentration achieved (cmax), time to maximum serum concentration achieved (tmax), and bioavailability (compared to iv ketorolac) when ketorolac is administered intranasally using a mad.

Eligibility criteria:
inclusion criteria: * present to the emergency department with a painful condition for which the treating physician decides to administer ketorolac as part of their usual care. exclusion criteria: * known allergy to ketorolac * contraindication to receiving ketorolac * receiving any nsaid within the past 6 hours * presence of an intranasal obstruction that cannot be readily cleared using suction or nose-blowing * inability to speak english or spanish * critical illness

Keywords: intranasal ketorolac pharmacokinetics pediatric
inspiratory flow parameters and handling of easyhaler and turbuhaler inhalers

Conditions: Asthma; Pulmonary Disease, Chronic Obstructive

Summary: the aim of the study is to measure the inspiratory flow that the different patient groups (asthmatic children, adults and elderly, as well as chronic obstructive pulmonary disease (copd) patients) generate through empty easyhaler (two versions) and turbuhaler inhalers. in addition, the handling and acceptability of the inhalers will be compared in asthmatic children.


Eligibility criteria:
inclusion criteria: * written informed consent obtained. * documented diagnosis of asthma and/or copd (a range of different severities for both diseases). * age: 6 years or above. exclusion criteria: * any severe chronic respiratory disease other than asthma or copd. * acute respiratory infection. * concurrent participation in a clinical drug study. * inability to perform repeatable spirometric measurements. * any medical condition that in the opinion of the investigator would endanger the subject if he/she participates in the study (such as contraindications to spirometry).